Vimarsana
Biggest News Aggregation in the World

Page 31 - Neurological Sciences News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Neurological Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Neurological Sciences Today - Breaking & Trending Today

Tiziana Life Sciences Hosting Key Opinion Leader Virtual Event to Discuss the Intranasal Delivery of Foralumab in Multiple Sclerosis - Vimarsana News

Tiziana Life Sciences Hosting Key Opinion Leader Virtual Event to Discuss the Intranasal Delivery of Foralumab in Multiple Sclerosis

Press release content from Globe Newswire. The AP news staff was not involved in its creation.

Source: apnews.com
COVID-19 Causes Changes in the Brain, Study Finds - Vimarsana News

COVID-19 Causes Changes in the Brain, Study Finds

COVID-19 can result in changes in brain structure and function, according to a study in the journal ‘Nature.’ Scientists say more research is needed.

News | Wu Tsai Neurosciences Institute - Vimarsana News

News | Wu Tsai Neurosciences Institute

To understand what causes brain degeneration, Wu Tsai Neuro scientists are looking beyond the brain's neurons and synapses to explore the vast infrastructure that supports them.

Alzheimer's risk genes linked to brain vasculature by new genetic atlas - Vimarsana News

Alzheimer's risk genes linked to brain vasculature by new genetic atlas

To understand what causes Alzheimer’s disease and other forms of brain degeneration, scientists may need to look beyond the brain’s computational units,

TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the American Academy of Neurology Annual Meeting - Vimarsana News

TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the American Academy of Neurology Annual Meeting

TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the American Academy of Neurology Annual Meeting - read this article along with other careers information, tips and advice on BioSpace